Do Side Effects Mean the Immunotherapy Is Working? — What the Link Really Is

No — not a reliable one. Immunotherapy side effects happen because checkpoint inhibitors release the brakes on your immune system broadly, across healthy tissue, not because they've specifically found and attacked the tumour. A side effect is a sign your immune system is more active — it is not a scan, and it is not proof your cancer is shrinking.

This confusion is understandable: it's natural to want an early, felt signal that treatment is working. But NCCN and ASCO guidance on immune checkpoint inhibitors is consistent on this point — response is judged by imaging and tumour markers on a set schedule, never by counting symptoms week to week.

No. Some patients who respond very well to immunotherapy have almost no side effects, and some patients with several side effects don't respond at all — the two things are driven by separate biology and don't move together in any pattern you can use day to day. Research has looked for a usable link across many immune-related effects, and for almost all of them, none has been found reliable enough to guide a real decision.

The table below lists common on-treatment effects, when each typically starts, and whether it has ever been meaningfully linked to response in research — the same "typically starts" reference used across our side-effect pages, extended here to answer the "does it mean it's working" question directly.

Neither reason, on its own, decides anything. Pausing or adjusting immunotherapy is a clinical decision your oncology team makes based on how severe the specific side effect is — its grade — never on a belief about what that side effect means for your cancer. Equally, having no side effects is never treated as a reason to stop early or as evidence to change the plan.

• Mild (Grade 1) effects are usually monitored and managed while treatment continues on schedule.
• Moderate (Grade 2) effects may mean pausing the current cycle while the reaction is treated, then reviewing before the next dose.
• Severe (Grade 3–4) effects need same-day medical attention and treatment is paused while the reaction is actively managed.
• No effects at all is not, by itself, a reason to change anything about your plan.

This grading follows NCCN/ASCO management guidance for immune-related adverse events. Never pause, skip, or adjust a dose yourself based on how you think treatment is going — that call belongs to your oncology team, made from your grading, your scans, and your overall picture together.

Checkpoint inhibitors work by releasing a brake — usually PD-1, PD-L1 or CTLA-4 — that normally keeps the immune system in check. Once that brake is released, immune cells can attack the tumour, but the same released brake also lets immune cells act more freely against healthy tissue anywhere in the body: skin, gut, thyroid, lungs, joints, and more. These are two separate outcomes of the same mechanism, not one causing the other, which is exactly why the strength of one doesn't predict the strength of the other.

This is the framing used in NCCN and ASCO management guidelines for immune-related adverse events: irAEs and anti-tumour response are tracked and graded as two independent things, with independent monitoring pathways, precisely because they don't reliably track each other.

Response assessment relies on scheduled tests, not on symptoms reported between visits. Here is what that looks like in practice, step by step.

1. 1

   Baseline imaging before treatment starts

   A CT scan (and PET-CT where relevant, coordinated at a partner imaging centre) establishes the starting picture your later scans are compared against.

2. 2

   Scheduled follow-up scans

   Imaging is repeated at intervals set by your oncologist — typically every 2–3 cycles — regardless of how many or how few side effects you've had in between.

3. 3

   Relevant tumour markers

   Where a marker is useful for your cancer type, blood tests track it alongside imaging, not as a replacement for it.

4. 4

   Clinical review at every visit

   Your oncologist reviews scans, markers, and how you're feeling together — no single piece decides the picture alone.

5. 5

   Side-effect monitoring runs in parallel, not instead

   irAEs are tracked and graded on their own timeline throughout, so a symptom is managed appropriately whatever the scans eventually show.

This question has a mirror image, and several companion pages worth reading alongside it.

• No Side Effects at All — Is the Treatment Working? — the other direction of this exact worry, answered in full.
• Loss of Appetite and Weight Change on Immunotherapy — a common whole-body effect that, like the others here, isn't a response signal either way.
• Joint and Muscle Pain on Immunotherapy — when it's ordinary immune activity and when it needs review.
• Nausea and Vomiting on Immunotherapy: Less Common Than You Expect — what's typical, and the red flags that aren't.
• Immunotherapy at CION Cancer Clinics — how we monitor both response and side effects together, from the first infusion onward.

Your Care Team Tracks Both Sides of This Question

Response and side effects are monitored on separate, scheduled tracks by the same multidisciplinary team throughout your treatment.